Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lypressin

FDA-approved product (solution, nasal), marketed as Diapid.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Lypressin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Lypressin. Its therapeutic class is shown instead.

WHO therapeutic group
Vasopressin and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lypressin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lypressin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Terlipressin for Refractory Septic Shock

    NCT04339868 · start 2020-04-03

    Registered record
    Registry ID
    NCT04339868
    Conditions
    Septic Shock; Refractory Shock; Norepinephrine Adverse Reaction
    Interventions
    Terlipressin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-04-03
    Completion
    2025-07-31
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock; Refractory Shock; Norepinephrine Adverse Reaction
    InterventionTerlipressin; Placebo
    PhasePhase 2
    Registry statusUnknown

  • The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy

    NCT04221672 · start 2019-11-07

    Registered record
    Registry ID
    NCT04221672
    Conditions
    Terlipressin Adverse Reaction; Ascites Hepatic; Liver Failure; Acute Kidney Injury
    Interventions
    Terlipressin plus standard care; Standard care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-11-07
    Completion
    2020-12-30
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTerlipressin Adverse Reaction; Ascites Hepatic; Liver Failure; Acute Kidney Injury
    InterventionTerlipressin plus standard care; Standard care
    PhasePhase 3
    Registry statusUnknown

  • 2- Day vs. 5- Day Terlipressin and Ceftriaxone in the Control Acute Gastroesophageal Variceal Hemorrhage

    NCT04056806 · start 2019-08

    Registered record
    Registry ID
    NCT04056806
    Conditions
    Variceal Rebleeding Rate and Infections
    Interventions
    Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-08
    Completion
    2022-08
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVariceal Rebleeding Rate and Infections
    InterventionTerlipressin 1Mg Powder for Conventional Release Solution for Injection Vial
    PhasePhase 4
    Registry statusUnknown

  • Methylene Blue Versus Vasopressin Analogue for Treatment of Septic Shock in Preterm Neonate

    NCT04110418 · start 2019-02-19

    Registered record
    Registry ID
    NCT04110418
    Conditions
    Neonatal Sepsis; Refractory Shock
    Interventions
    Methylene Blue
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-02-19
    Completion
    2020-02-19
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeonatal Sepsis; Refractory Shock
    InterventionMethylene Blue
    PhasePhase 2
    Registry statusUnknown

  • Terlipressin Infusion Alone Vs Terlipressin With Noradrenaline Infusion In The Treatment of Hepatorenal Syndrome Type 1

    NCT03822091 · start 2019-01-28

    Registered record
    Registry ID
    NCT03822091
    Conditions
    Type 1 HEPATO RENAL SYNDROME(HRS)
    Interventions
    Terlipressin; Terlipressin and Noradrenaline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-01-28
    Completion
    2020-01-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 HEPATO RENAL SYNDROME(HRS)
    InterventionTerlipressin; Terlipressin and Noradrenaline
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of Early Association of Terlipressin and Norepinephrine During Septic Shock; the TerliNor Study

    NCT03336814 · start 2018-07-27

    Registered record
    Registry ID
    NCT03336814
    Conditions
    Septic Shock
    Interventions
    Terlipressin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-07-27
    Completion
    2019-06-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionTerlipressin; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Efficacy of Terlipressin Therapy in Acute Variceal Haemorrhage After EVL

    NCT03584087 · start 2018-05-07

    Registered record
    Registry ID
    NCT03584087
    Conditions
    Acute Variceal Haemorrhage
    Interventions
    Normal Saline; Terlipressin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-05-07
    Completion
    2019-07-31
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Variceal Haemorrhage
    InterventionNormal Saline; Terlipressin
    PhasePhase 4
    Registry statusCompleted

  • Effect of Terlipressin on Cerebral Oxygen Saturation During Liver Transplantation

    NCT03395574 · start 2018-01-25

    Registered record
    Registry ID
    NCT03395574
    Conditions
    Terlipressin Adverse Reaction; Liver Transplantation
    Interventions
    Terlipressin; Normal saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-01-25
    Completion
    2018-11-25
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTerlipressin Adverse Reaction; Liver Transplantation
    InterventionTerlipressin; Normal saline
    PhasePhase 2
    Registry statusCompleted

  • Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding

    NCT04358016 · start 2018-01-01

    Registered record
    Registry ID
    NCT04358016
    Conditions
    Cirrhosis, Liver; Upper Gastrointestinal Bleeding
    Interventions
    Terlipressin; Somatostatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-01-01
    Completion
    2020-03-01
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis, Liver; Upper Gastrointestinal Bleeding
    InterventionTerlipressin; Somatostatin
    PhasePhase 4
    Registry statusCompleted

  • Comparison of Articaine and Prilocaine for Extraction of Maxillary Teeth

    NCT04236115 · start 2017-09-20

    Registered record
    Registry ID
    NCT04236115
    Conditions
    Overcoming the Failure of Anaesthesia; Maxillary Teeth; Dental Extraction
    Interventions
    Articaine 4%; Prilocain 3%; Adrenalin; Felypressin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-09-20
    Completion
    2018-06-20
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvercoming the Failure of Anaesthesia; Maxillary Teeth; Dental Extraction
    InterventionArticaine 4%; Prilocain 3%; Adrenalin; Felypressin
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Terlipressin With Albumin Versus Midodrine With Albumin Versus Albumin Alone in Prevention of Paracentesis Induced Circulatory Dysfunction in Cirrhosis

    NCT03144713 · start 2017-05-28

    Registered record
    Registry ID
    NCT03144713
    Conditions
    Cirrhosis
    Interventions
    Terlipressin; Midodrine; Albumin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-05-28
    Completion
    2018-04-30
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis
    InterventionTerlipressin; Midodrine; Albumin
    PhaseNot applicable
    Registry statusCompleted

  • Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1

    NCT02770716 · start 2016-07-13

    Registered record
    Registry ID
    NCT02770716
    Conditions
    Hepatorenal Syndrome
    Interventions
    Terlipressin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-07-13
    Completion
    2019-07-24
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatorenal Syndrome
    InterventionTerlipressin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase

    NCT02788240 · start 2016-05-01

    Registered record
    Registry ID
    NCT02788240
    Conditions
    Acute on Chronic Liver Failure
    Interventions
    Peg GCSF; 20% Albumin; Nutrition; Bowel wash; Terlipressin 1- 4mg,if indicated; Meropenem or Imepenem, if indicated; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2016-05-01
    Completion
    2017-07-15
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute on Chronic Liver Failure
    InterventionPeg GCSF; 20% Albumin; Nutrition; Bowel wash +3 more
    PhaseNot applicable
    Registry statusTerminated

  • Terlipressin Infusion During Whipple Procedure: Effect on Blood Loss and Transfusion Needs

    NCT03572088 · start 2016-05

    Registered record
    Registry ID
    NCT03572088
    Conditions
    Terlipressin; Blood Loss
    Interventions
    Terlipressin; normal saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-05
    Completion
    2017-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTerlipressin; Blood Loss
    InterventionTerlipressin; normal saline
    PhasePhase 2
    Registry statusCompleted

  • Effect of Terlipressin Infusion on Systemic and Hepatic Hemodynamics During Hepatobiliary Surgery

    NCT02718599 · start 2016-04

    Registered record
    Registry ID
    NCT02718599
    Conditions
    Hemodynamics, Liver, Terlipressin
    Interventions
    terlipressin; normal saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-04
    Completion
    2017-07
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemodynamics, Liver, Terlipressin
    Interventionterlipressin; normal saline
    PhasePhase 2
    Registry statusCompleted